170277-31-3

Basic information

• Product Name: Infliximab
• Synonyms: Avakine;Immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal ca2 heavy chain), disulfide with human-mouse monoclonal ca2 light chain, dimer;Remicade;Unii-B72hh48flu;CT-P 13
• CAS NO: 170277-31-3
• Molecular Weight: 0
• Mol File: 170277-31-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Infliximab(CAS DataBase Reference)
• NIST Chemistry Reference: Infliximab(170277-31-3)
• EPA Substance Registry System: Infliximab(170277-31-3)

Safety Data

• Hazardous Substances Data: 170277-31-3(Hazardous Substances Data)

Usage

Description

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a cytokine involved in inflammatory and immune responses. It is engineered by combining the variable regions of a mouse anti-TNF-α antibody with the constant region of a human IgG1 antibody, resulting in a protein that can specifically bind to and neutralize TNF-α. This interaction helps to reduce inflammation and alleviate symptoms associated with various inflammatory conditions.

Uses

Used in Pharmaceutical Industry:
Infliximab is used as a therapeutic agent for the treatment of various inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriasis. It functions by inhibiting the pro-inflammatory effects of TNF-α, thereby reducing inflammation and improving the quality of life for patients suffering from these conditions.
Used in Cancer Treatment:
Infliximab is also used in combination with other agents, such as harmine and related compounds, to target the transcription factor NF-κB for the treatment of cancers. By inhibiting NF-κB, Infliximab can help suppress the growth and progression of cancer cells, making it a valuable component in cancer therapy regimens.